Rabbit Polyclonal DVL1 Antibody

+ +

•  

   
     Anti-DVL1 Antibody (Center)at  1:1000 dilution + PC-3 whole cell lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 75 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     All lanes : Anti-DVL1 Antibody (Center) at 1:2000 dilution Lane 1: K562 whole cell lysates Lane 2: MDA-MB-453 whole cell lysates Lane 3: PC-3 whole cell lysates Lane 4: human kidney lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 75 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HepG2 (human liver hepatocellular carcinoma cell line) cells labeling DVL1 with P33217 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG  secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on HepG2 cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin  at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).    

•  

   
     P33217 staining DVL1 in human skeletal muscle sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

The DVL1 antibody is a crucial tool for studying the Dishevelled-1 (DVL1) protein, a key component of the Wnt signaling pathway. DVL1. part of the Dishevelled (DVL) family (DVL1. DVL2. DVL3), acts as a signaling scaffold that regulates both canonical (β-catenin-dependent) and non-canonical Wnt pathways, influencing processes like embryonic development, cell polarity, and tissue homeostasis. Dysregulation of DVL1 is linked to cancers, developmental disorders, and other diseases, making it a target for mechanistic and therapeutic research.

Structurally, DVL1 contains three conserved domains: DIX (for protein oligomerization), PDZ (mediating protein interactions), and DEP (membrane localization). Antibodies targeting these domains or specific phosphorylation sites help detect DVL1 expression, localization, and post-translational modifications. Researchers use DVL1 antibodies in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to explore its role in Wnt signaling dynamics or disease contexts.

Commercially available DVL1 antibodies are typically raised in rabbits or mice, with monoclonal or polyclonal formats offering varying specificity. Validation data (e.g., knockout controls) are critical due to potential cross-reactivity with DVL2/DVL3. These reagents are essential for studying Wnt-driven pathologies, including colorectal cancer, neurodegenerative diseases, and skeletal abnormalities, providing insights into DVL1’s dual roles as a signaling hub and potential therapeutic target.